Development and specification of physiologically based pharmacokinetic models for use in risk assessment.

Risk assessments are performed to estimate the conditions under which individuals or populations may be harmed by exposure to environmental or occupational chemicals. In the absence of quantitative data in the human, this process is often dependent upon the use of animal and in vitro data to estimate human response. To reduce the uncertainty inherent in such extrapolations, there has been considerable interest in the development of physiologically based pharmacokinetic (PBPK) models of toxic chemicals for application in quantitative risk assessments. PBPK models are effective tools for integrating diverse dose-response and mechanistic data in order to more accurately predict human risk. Yet, for these models to be useful and trustworthy in performing the necessary extrapolations (species, doses, exposure scenarios), they must be thoughtfully constructed in accordance with known biology and pharmacokinetics, documented in a form that is transparent to risk assessors, and shown to be robust using diverse and appropriate data. This paper describes the process of PBPK model development and highlights issues related to the specification of model structure and parameters, model evaluation, and consideration of uncertainty. Examples are provided to illustrate approaches for selecting a "preferred" model from multiple alternatives.

[1]  H J Clewell,et al.  Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. , 1996, Toxicology.

[2]  M E Andersen,et al.  Saturable metabolism and its relationship to toxicity. , 1981, Critical reviews in toxicology.

[3]  Melvin E. Andersen,et al.  Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat , 1990 .

[4]  C J Portier,et al.  Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[5]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[6]  B. Allen,et al.  Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. , 1989, Toxicology letters.

[7]  H W Leung,et al.  Development and utilization of physiologically based pharmacokinetic models for toxicological applications. , 1991, Journal of toxicology and environmental health.

[8]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[9]  P O Droz,et al.  A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. , 1996, Toxicology and applied pharmacology.

[10]  G. Johanson,et al.  A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. , 2001, Toxicology and applied pharmacology.

[11]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .

[12]  John C Lipscomb,et al.  Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment , 2001, Toxicology and industrial health.

[13]  R H Reitz,et al.  In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. , 1989, Toxicology and applied pharmacology.

[14]  Jeffery M. Gearhart,et al.  A Partition Coefficient Determination Method for Nonvolatile Chemicals in Biological Tissues , 1994 .

[15]  L S Birnbaum,et al.  Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species. , 1983, Toxicology and applied pharmacology.

[16]  H. Bolt,et al.  Pharmacokinetics of halogenated ethylenes in rats , 1978, Archives of Toxicology.

[17]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[18]  L Finkelstein,et al.  Modeling and identification of metabolic systems. , 1981, The American journal of physiology.

[19]  M. Andersen,et al.  Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. , 1984, Toxicology and applied pharmacology.

[20]  M C Kohn,et al.  Achieving credibility in risk assessment models. , 1995, Toxicology letters.

[21]  Kannan Krishnan,et al.  Incorporation of Pharmacokinetic and Pharmacodynamic Data into Risk Assessments , 2004, Toxicology mechanisms and methods.

[22]  Hugh A Barton,et al.  Evaluation of physiologically based pharmacokinetic models for use in risk assessment , 2007, Journal of applied toxicology : JAT.

[23]  Lewis B. Sheiner,et al.  Extended least squares nonlinear regression: A possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic data , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  H J Clewell,et al.  Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. , 2000, Environmental health perspectives.

[25]  R. Clewell,et al.  The use of physiologically based models to integrate diverse data sets and reduce uncertainty in the prediction of perchlorate and iodide kinetics across life stages and species , 2001, Toxicology and industrial health.

[26]  P. Åstrand,et al.  Textbook of Work Physiology , 1970 .

[27]  G. L. Kedderis,et al.  Incorporating human interindividual biotransformation variance in health risk assessment. , 2002, The Science of the total environment.

[28]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[29]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[30]  A Sato,et al.  A vial-equilibration method to evaluate the drug-metabolizing enzyme activity for volatile hydrocarbons. , 1979, Toxicology and applied pharmacology.

[31]  M. Andersen,et al.  Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes , 1998, Archives of Toxicology.

[32]  A. Monro,et al.  What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? , 1992, Toxicology and applied pharmacology.

[33]  Richard A Corley,et al.  Evaluation of Physiologically Based Models of Pregnancy and Lactation for Their Application in Children's Health Risk Assessments , 2003, Critical reviews in toxicology.

[34]  R. J. Lutz,et al.  A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[35]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.

[36]  P O Droz,et al.  A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. , 1996, Toxicology and applied pharmacology.

[37]  Ellen J. O'Flaherty,et al.  Interspecies Conversion of Kinetically Equivalent Doses1 , 1989 .

[38]  H J Clewell,et al.  Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. , 1996, Toxicology.

[39]  David C. Chalupa,et al.  Quantitative exposure of humans to an octamethylcyclotetrasiloxane (D4) vapor. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[41]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. , 1991, Toxicology and applied pharmacology.

[42]  G. W. Jepson,et al.  Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. , 1994, Environmental health perspectives.

[43]  Hugh A Barton,et al.  Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.

[44]  H J Clewell,et al.  Biologically motivated models for chemical risk assessment. , 1989, Health physics.

[45]  M E Andersen,et al.  Development of a physiologically based pharmacokinetic model for chloroform. , 1990, Toxicology and applied pharmacology.

[46]  A Sato,et al.  Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. , 1979, British journal of industrial medicine.

[47]  J W Fisher,et al.  Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. , 2000, Environmental health perspectives.

[48]  R A Corley,et al.  Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.

[49]  M E Andersen,et al.  Determining kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. , 1989, Toxicology and applied pharmacology.

[50]  M E Andersen,et al.  Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. , 1989, Toxicology and applied pharmacology.

[51]  H J Clewell,et al.  A physiologically based simulation approach for determining metabolic constants from gas uptake data. , 1986, Toxicology and applied pharmacology.

[52]  H J Clewell,et al.  A physiological pharmacokinetic model for dermal absorption of vapors in the rat. , 1986, Toxicology and applied pharmacology.

[53]  H J Clewell,et al.  Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.

[54]  Harvey J Clewell,et al.  Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage , 2007, Journal of toxicology and environmental health. Part A.

[55]  Richard D. Thomas Drinking Water and Health , 1986 .

[56]  M E Andersen,et al.  Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[57]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[58]  H A el-Masri,et al.  Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. , 1995, Toxicology.

[59]  Gunnar Johanson,et al.  A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation , 2005, Archives of Toxicology.

[60]  M E Andersen,et al.  Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. , 1991, Toxicology and applied pharmacology.

[61]  P. Watanabe,et al.  Fate of (14C)vinyl chloride after single oral administration in rats. , 1976, Toxicology and applied pharmacology.

[62]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[63]  Stephen S. Olin,et al.  Low-dose extrapolation of cancer risks : issues and perspectives , 1995 .

[64]  F Y Bois,et al.  Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. , 2000, Environmental health perspectives.

[65]  R L Dedrick,et al.  Species similarities in pharmacokinetics. , 1980, Federation proceedings.

[66]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[67]  Fredrik U. Jönsson,et al.  Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[68]  M E Andersen,et al.  Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. , 1980, Toxicology and applied pharmacology.

[69]  G W Jepson,et al.  A partition coefficient determination method for nonvolatile chemicals in biological tissues. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[70]  F E Yates,et al.  Good manners in good modeling: mathematical models and computer simulations of physiological systems. , 1978, The American journal of physiology.

[71]  Malcolm Rowland,et al.  Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[72]  Ewart R. Carson,et al.  The mathematical modeling of metabolic and endocrine systems : model formulation, identification, and validation , 1983 .

[73]  P O Droz,et al.  Variability in biological monitoring of organic solvent exposure. II. Application of a population physiological model. , 1989, British journal of industrial medicine.

[74]  Hugh A. Barton,et al.  Data for Physiologically Based Pharmacokinetic Modeling in Neonatal Animals: Physiological Parameters in Mice and Sprague-Dawley Rats , 2004 .

[75]  K. Krishnan,et al.  Molecular Structure-Based Prediction of the Toxicokinetics of Inhaled Vapors in Humans , 1999 .

[76]  W. L. Chiou,et al.  Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. , 1982, Journal of pharmaceutical sciences.

[77]  Hugh A Barton,et al.  Computational Pharmacokinetics During Developmental Windows of Susceptibility , 2005, Journal of toxicology and environmental health. Part A.

[78]  E. H. Twizell The mathematical modeling of metabolic and endocrine systems: E.R. Carson, C. Cobelli and L. Finkelstein John Wiley and Sons, Chichester, Sussex, UK, 394 pp., £45.15, 1983 , 1984 .

[79]  Vera Thomas,et al.  Biological-Mathematical Modeling of Chronic Toxicity. , 1981 .

[80]  Gunnar Johanson,et al.  A human physiological model describing acetone kinetics in blood and breath during various levels of physical exercise. , 2006, Toxicology letters.

[81]  Harvey J Clewell,et al.  Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. , 2006, Toxicology.

[82]  M E Andersen,et al.  Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. , 1990, Toxicology and applied pharmacology.

[83]  L Finkelstein,et al.  Validation of simple and complex models in physiology and medicine. , 1984, The American journal of physiology.

[84]  Christopher J. Portier,et al.  Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. , 1989 .

[85]  Harvey J Clewell,et al.  Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. , 2006, Regulatory toxicology and pharmacology : RTP.

[86]  Harvey J Clewell,et al.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[87]  H J Clewell,et al.  Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. , 1986, Toxicology and applied pharmacology.

[88]  Tammie R. Covington,et al.  Evaluation of the Potential Impact of Age- and Gender-Specific Lung Morphology and Ventilation Rate on the Dosimetry of Vapors , 2003, Inhalation toxicology.

[89]  M. Andersen,et al.  Metabolism of inhaled brominated hydrocarbons: validation of gas uptake results by determination of a stable metabolite. , 1982, Toxicology and applied pharmacology.

[90]  E. Adolph,et al.  Quantitative Relations in the Physiological Constitutions of Mammals. , 1949, Science.

[91]  M C Kohn,et al.  The importance of anatomical realism for validation of physiological models of disposition of inhaled toxicants. , 1997, Toxicology and applied pharmacology.

[92]  K. Krishnan,et al.  Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. , 2005, Chemical research in toxicology.

[93]  H J Clewell,et al.  Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[94]  H J Clewell,et al.  Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. , 1999, Risk analysis : an official publication of the Society for Risk Analysis.

[95]  H J Clewell,et al.  Physiologically-Based Pharmacokinetic Modeling and Bioactivation of Xenobiotics , 1994, Toxicology and industrial health.

[96]  Harvey J Clewell,et al.  Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. , 2003, Regulatory toxicology and pharmacology : RTP.

[97]  P O Droz,et al.  Variability in biological monitoring of solvent exposure. I. Development of a population physiological model. , 1989, British journal of industrial medicine.

[98]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. , 1989, Toxicology and applied pharmacology.

[99]  M E Andersen,et al.  Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[100]  H J Clewell,et al.  A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.

[101]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[102]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[103]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[104]  Aldo Rescigno,et al.  The use and abuse of models , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[105]  G. Johanson,et al.  Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. , 1986, Toxicology letters.

[106]  E J O'Flaherty,et al.  Physiologically based models for bone-seeking elements. V. Lead absorption and disposition in childhood. , 1995, Toxicology and applied pharmacology.

[107]  H J Clewell,et al.  Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[108]  Harvey J Clewell,et al.  The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.

[109]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling , 2010 .

[110]  V. Fiserova-Bergerova,et al.  Predictable "individual differences" in uptake and excretion of gases and lipid soluble vapours simulation study. , 1980, British journal of industrial medicine.

[111]  F Y Bois,et al.  Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. , 1990, Toxicology and applied pharmacology.

[112]  R H Reitz,et al.  Disposition of radioactivity in fischer 344 rats after single and multiple inhalation exposure to [(14)C]Octamethylcyclotetrasiloxane ([(14)C]D(4)). , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[113]  H J Clewell,et al.  Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). , 1993, Toxicology letters.

[114]  M E Andersen,et al.  Modeling the tissue solubilities and metabolic rate constant (Vmax) of halogenated methanes, ethanes, and ethylenes. , 1988, Toxicology letters.

[115]  B. Stahl,et al.  A pharmacodynamic model of triglyceride transport and deposition during feed deprivation or following treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the rat. , 1993, Toxicology and applied pharmacology.